Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2Phase 2 1

Status

Active not recruiting 3Completed 2Recruiting 1

Sponsor Class

OTHER 4NIH 1INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6

Conditions

Multiple Myeloma 85Recurrence 9Immunoglobulin Light-chain Amyloidosis 6Neoplasms, Plasma Cell 3Plasmacytoma 2Lymphoma 2Leukemia, Plasma Cell 2Hematologic Neoplasms 2Amyloidosis 2Smoldering Multiple Myeloma 1Proteostasis Deficiencies 1POEMS Syndrome 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Hematologic Diseases 1Genetic Diseases, Inborn 1Chromosome 17 deletion 1Alzheimer Disease 1

Interventions

Dexamethasone 50Melphalan 29Cyclophosphamide 25Bortezomib 24Filgrastim 18Calcium Dobesilate 18Peripheral Blood Stem Cell Transplantation 16daratumumab 13pomalidomide 10dexamethasone acetate 8Lenalidomide 8fludarabine phosphate 7ixazomib 6dexamethasone 21-phosphate 6Whole-Body Irradiation 6Mycophenolic Acid 6venetoclax 5birtamimab 5auricularum 5Thalidomide 5Granulocyte Colony-Stimulating Factor 5Cyclosporine 5Busulfan 5Radiotherapy 4Interferon-alpha 4Etoposide 4Carboplatin 4Biopsy 4sargramostim 3miridesap 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Immunoglobulin Light-chain Amyloidosis × ixazomib × Plasma cell × Clear all
NCT04847453 2026-05-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03283917 2026-02-27

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
21 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03618537 2025-12-04

Ixazomib Maintenance Study in Patients With AL Amyloidosis

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
17 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

NCT03236792 2022-09-29

Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
28 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT01318902 2020-04-01

Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis

Takeda

Phase 1 Completed
27 enrolled 34 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡